Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Labcyte BLOG

How Personalized is Personalized Medicine?
MONDAY, SEPTEMBER 26, 2016
linkedin twitter facebook |  42Shares

Just how personalized is today’s personalized medicine? Krister Wennerberg, Labcyte customer and collaborator at Finland’s Institute for Molecular Medicine (FIMM) discussed the topic on Mendelspod, highlighting a novel way that his institute is combining different types of studies to make treatment more individualized.


FIMM’s “individualized systems medicine” combines traditional molecular profiling with functional profiling and clinical information in order to get a better picture of the patient’s disease, he explains. The group first tested this approach, which involves taking primary cells from patients and testing their cells ex vivo with a variety of drugs to see what kills the cancer, in patients with late-stage leukemia. The idea is to have a quick way of predicting what a patient might respond to.


“The question is how can we find new therapies that work for new subpopulations of a disease and then with that, over time, have a better cure rate of a disease,” he says. In addition, they are looking at how to predict effectiveness of drug combinations, “because ultimately, in most cases, we are going to need combinations of drugs to treat these diseases.”


Wennerberg described how acoustic dispensing, which provides the ability to move nanoliter volumes of liquids with sound, enables this work. “That’s very powerful when you add the drugs to the cells,” he says, noting they can add the drugs at whatever volume they want and in whichever well they want, and can do combinations very effectively.


He describes the power of using acoustic liquid handling to add the cells to the plates because, when working with very small numbers of cells, conventional liquid handling may actually have too much dead volume and lose all the cells in the tubing. “We also like it for other types of follow-up assays,” he says. “So it’s a technology we rely on a lot for many different parts of the process…The big point is to get as much as possible out of the samples, and it allows us to do that.”


Tune in at Mendelspod.com to listen to the full conversation. You can also read more about FIMM’s work here.